Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCTRobert Chen, Stephen J. Forman, Peter Martin et al.|Blood|2015Cited by 13